Decrease of CD44-positive cells correlates with tumor response to chemotherapy in patients with gastrointestinal cancer

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 1747-1756

  Palagani, Vindhya ^a   El Khatib, Mona ^a   Krech, Till ^b   Manns, Michael P ^b   Malek, Nisar P ^a   Plentz, Ruben R ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

CA19 9; Cancer stem cells; CD44; Chemotherapy; Gastrointestinal cancer; KP3 cells; SW480; Tumor marker

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; FLUOROURACIL; HERMES ANTIGEN; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT RESPONSE; TUMOR GROWTH;

AGED; ANTIGENS, CD44; CA-19-9 ANTIGEN; CELL LINE, TUMOR; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84861503490     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Quante M and Wang TC: Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 6: 724-737, 2009.
2. Alison MR, Lim SM and Nicholson LJ: Cancer stem cells: problems for therapy ? J Pathol 223: 147-161, 2011.
3. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001. (Pubitemid 33041634)
4. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997. (Pubitemid 27298715)
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
6. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AI, DiMeco F, Olivi A and Eberhardt CG: Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25: 2524- 2533, 2007.
7. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003. (Pubitemid 37187480)
8. Maund SL and Cramer SD: The tissue-Specific stem cell as target for chemoprevention. Stem Cell Rev 7: 307-314, 2011.
9. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
10. Monteiro J and Fodde R: Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer 46: 1198-1203, 2011.
11. Naor D, Sionov RV and Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319, 1997. (Pubitemid 27197761)
12. Lesley J, Hyman R, English N, Catterall JB and Turner GA: CD44 in inflammation and metastasis. Glycoconj J 14: 611-622, 1997. (Pubitemid 27353205)
13. Marhaba R and Zoller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35: 211-231, 2000.
14. Lee CJ, Li C and Simeone DM: Human pancreatic cancer stem cells: implications for how we treat pancreatic cancer. Transl Oncol 1: 14-18, 2008.
15. Todaro M, Francipane MG, Medema JP and Stassi G: Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138: 2151-2162, 2010.
16. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27: 1006-1020, 2009.
17. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
18. Mulder JW, Kruyt PM, Sewnath M, Ossting J, Seldenrijk CA, Weidema WF, Offerhaus GJ and Pals ST: Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344: 1470-1472, 1994. (Pubitemid 24351702)
19. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I and Johnson JP: De novo expression of CD44 and survival in gastric cancer. Lancet 342: 1019-1022, 1993. (Pubitemid 23314804)
20. Koretz K, Moller P, Lehnert T, Hinz U, Otto HF and Herfarth C: Effect of CD44v6 on survival in colorectal carcinoma. Lancet 345: 327-328, 1995.
21. Hong RL, Lee WJ, Shun CT, Chu JS and Chen YC: Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology 52: 334-339, 1995.
22. Ylagan LR, Scholes J and Demopoulos R: CD44: a marker of squamous differentiation in adenosquamous neoplasms. Arch Pathol Lab Med 124: 212-215, 2000. (Pubitemid 30090604)
23. Yamamichi K, Uehara Y, Kitamura N, Nakane Y and Hioki K: Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer 79: 256-262, 1998. (Pubitemid 28262210)
24. Takada M, Yamamoto M and Saitoh Y: The significance of CD44 in human pancreatic cancer: I. High expression of CD44 in human pancreatic adenocarcinoma. Pancreas 9: 748-752, 1994. (Pubitemid 24317828)
25. Gansauge F, Gansauge S, Zobywalski A, Scharnweber C, Link KH, Nussler AK and Beger HG: Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Cancer Res 55: 5499-5503, 1995.
26. Gotoda T, Matsumura Y, Kondo H, Ono H, Kanamoto A, Kato H, Watnabe H, Tachimori Y, Nakaniski Y and Kakizoe T: Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma. Gut 46: 14-19, 2000. (Pubitemid 30307670)
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabekke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
28. Ponta H, Sherman L and Herrlich PA: CD44. from adhesion molecules to signalling regulators, Nat Rev Mol Cell Biol 4: 33- 45, 2003.
29. Terpe HJ, Stark H, Prehm P and Gunthert U: CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. Histochemistry 101: 79- 89, 1994.
30. Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Sima HR, Esmaili-Shandiz E, Hosseinnezhad H, Taqhizadeh-Kermani A, Moaven O and Bahrani M: Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol 14: 6376-6381, 2008.
31. Hong SP, Wen J, Bang S, Park S and Song SY: CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125: 2323-2331, 2009.
32. Immervoll H, Hoem D, Steffensen OJ, Miletic H and Molven A: Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem 59: 441-455, 2011.
33. Gazzaniga P, Gradilone A, Petracca A, Nicolazzo C, Raimondi C, Iacovelli R, Naso G and Cortesi E: Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. J Cell Mol Med 14: 2073-2077, 2011.
34. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH and Majumdar AP: Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol 2: 321-328, 2009.
35. Jin G, Ramanathan V, Quante M, Baik GH, Yang X, Wang SS, Tu S, Gordon SA, Pritchard DM, Varro A, Shulkes A and Wang TC: Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice. J Clin Invest 119: 2691-2701, 2009.
36. Jimeno A, Feldmann G, Suarez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, Garcia-Garcia E, Lopez-Rios F, Matsui W, Maitra A and Hildago M: A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 8: 310-314, 2009.